Asset profile

Alectinib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-10-31.

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (5)
October 2026 (1)
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-10-31 · NCT03178552 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (2)
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-18 · NCT05987956 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT05713006 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-24 · NCT04322890 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
February 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-02-28 · NCT05987644 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
January 2029 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-01-01 · NCT03202940 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
June 2030 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-06-16 · NCT05170204 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.